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Abstract
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Malignant astrocytomas are highly invasive into adjacent and distant regions of the normal brain.
Rho GTPases are small monomeric G proteins that play important roles in cytoskeleton
rearrangement, cell motility, and tumor invasion. In the present study, we show that the knock
down of StarD13, a GTPase activating protein (GAP) for RhoA and Cdc42, inhibits astrocytoma
cell migration through modulating focal adhesion dynamics and cell adhesion. This effect is
mediated by the resulting constitutive activation of RhoA and the subsequent indirect inhibition of
Rac. Using Total Internal Reflection Fluorescence (TIRF)-based Förster Resonance Energy
Transfer (FRET), we show that RhoA activity localizes with focal adhesions at the basal surface
of astrocytoma cells. Moreover, the knock down of StarD13 inhibits the cycling of RhoA
activation at the rear edge of cells, which makes them defective in retracting their tail. This study
highlights the importance of the regulation of RhoA activity in focal adhesions of astrocytoma
cells and establishes StarD13 as a GAP playing a major role in this process.
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Introduction
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Gliomas, which are neuroepithelial brain tumors derived from astrocytes, oligodendrocytes,
or ependymal cells, constitute up to 80% of primary brain tumors in humans [1, 2].
Astrocytomas are gliomas that arise from astrocytes [1]. Malignant astrocytomas are usually
associated with poor prognosis and high mortality rate[3]. Malignant astrocytomas rarely
metastasize to other organs, but are highly invasive within the brain and could spread to
distant regions of the brain, which renders them surgically unmanageable and accounts for
their often fatal outcome [4].
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Invasion of glioma is a complex process consisting of several steps that involve coordinated
intracellular and extracellular interactions [4, 5]. Cell migration is an integral element of the
invasion process [4, 5]. To actively migrate, a cell follows a well-defined motility cycle that
is initiated in response to the detection of a chemoattractant. This commits the cell to
undergo actin polymerization transients in order to extend an actin-rich protrusion, such as
lamellipodia or filopodia, towards the direction of the chemoattractant [6]. The steps that
follow to achieve the motility cycle include formation of adhesion structures that stabilize
the protrusion [7], development of contractile force that translocates the cell body forward,
release of adhesion structures at the cell rear and finally retraction of the cell towards the
direction of motility [8]. These processes are regulated by Rho family of small guanosine
triphosphatases (GTPases), which includes key enzymes that play a major role in the
reorganization of the actin cytoskeleton [9].
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Rho GTPases are small monomeric G proteins of a 20–40 kDa molecular mass, which
belong to the Ras superfamily [10]. The three most characterized and studied members of
the Rho family are RhoA, Rac1, and Cdc42 [11]. It was initially believed that RhoA, Rac1
and Cdc42 regulate the formation of actin-myosin filaments, lamellipodia and filopodia
respectively [12]. However, recent studies taking into consideration the different effects of
Rho GTPases in different cell systems and the cross-talk between the signaling pathways
regulated by Rho GTPases, have shown that this model is too simplistic. For instance, the
role of RhoA during cell motility was initially thought to be restricted to the generation of
contractile force and focal adhesion turnover needed for tail retraction; however, it was
recently shown that RhoA is active at the cell edge [13, 14], and that this activation might
coordinate the Cdc42 and Rac-1 regulation of the actin cytoskeleton [14, 15]. Moreover, in
neutrophils, Rac activation was observed in the tail of the cells in addition to the leading
edge [16].
Rho GTPases are found in two forms, a GDP-bound inactive and a GTP-bound active form
[17]. As Rho GTPases govern a wide range of critical cellular functions, their function is
tightly regulated by three classes of proteins, Guanine nucleotide exchange factors (GEFs),
GTPase-activating proteins (GAPs), and guanine nucleotide dissociation inhibitors (GDIs).
GAPs negatively regulate Rho GTPases by stimulating the intrinsic GTPase activity of Rho
GTPases and promoting the formation of the inactive GDP-bound form [18]. StarD13,
which is also referred to as START-GAP2 or DLC2, is a Rho GAP that was first described
as a tumor suppressor in hepatocellular carcinoma [19]. This Rho-GAP, whose gene is
located on the position 13q12.3, specifically inhibits the function of RhoA and Cdc42 and
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was demonstrated to inhibit the Rho-mediated assembly of actin stress fibers in cultured
cells.
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Overexpression of StarD13 is associated with a decrease in cell growth [19]. Cancerprofiling arrays indicated that StarD13 expression is down-regulated in several types of solid
tumors including in renal, uterine, gastric, colon, breast, lung, ovarian, and rectal tumors
[20]. Furthermore, a Genome-Wide Analysis integrating a paired copy number and gene
expression survey on glioblastoma samples concluded that StarD13 is a potential tumor
suppressor gene that could be involved in the resistance of this tumor to etoposide [21].
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A study that aimed at examining the intracellular localization of StarD13 showed that it is
found in focal adhesions and that it is anchored to tensin2, a component of focal adhesions,
through a so-called focal adhesion targeting domain made of amino acids 318–472 in the Nterminal region [22]. StarD13 also plays a role in cell migration and attachment, where its
silencing was found to enhance the migration and decrease cell attachment in normal
vascular endothelial cells [23]. Moreover, StarD13 deficiency plays a role in the metastasis
of breast carcinoma into secondary sites. Using quantitative RT-PCR, a significantly low
expression of the StarD13 gene was detected in tumor samples taken from primary ductal
carcinomas from patients with metastases into a regional lymph node [20].
In this study, we investigate the role of StarD13-mediated RhoA regulation in astrocytoma
cell motility. The knockdown of StarD13 surprisingly inhibited astrocytoma cell motility.
This was shown to be mediated by the resulting constitutive activation of RhoA. Similar to
the effect of constitutive RhoA activation, StarD13 knockdown resulted in larger focal
adhesions. Consequently, the cells were unable to detach their tails, which prohibited the
completion of the motility cycle. This study highlights the importance of the regulation of
RhoA activity in astrocytoma cell motility and establishes StarD13 as the GAP playing a
major role in this process.

Materials and Methods
Cell Culture
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Human astrocytoma cell lines SF268 and T98G were cultured in DMEM medium
supplemented with 10% FBS and 100U penicillin/streptomycin at 37°C and 5% CO2 in a
humidified chamber.
Antibodies and reagents
Goat polyclonal anti-StarD13 antibody was obtained from Santa Cruz Biotechnology.
Mouse monoclonal anti-RhoA, mouse monoclonal anti-Rac1, and mouse monoclonal antipaxillin antibodies were purchased from Upstate biotechnology, Lake Placid, NY. The antiCdc42 antibody (Sc-87) was obtained from Santa Cruz Biotechnology. Anti-goat and antimouse HRP-conjugated secondary antibodies were obtained from Promega. Fluorescent
secondary antibodies (AlexaFluor 488) and Rhodamin Phalloidin were obtained from
Invitrogen. The full length GFP-StarD13 construct was a generous gift from Dr. Hitoshi
Yagisawa from the University of Hyogo, Japan (Mammalian expression plasmids for GFP
fusion proteins, pEGFPSTART-GAP1(wt)) [22]. The RhoA constructs were a generous gift
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from Dr. Hideki Yamaguchi and the Cherry-Rac-DA from Dr. Louis Hodgson from the
Albert Einstein College of Medicine, New York, USA.
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Cell transfection and small interfering RNA
Cells were transfected with 5 μg GFP-StarD13, Dominant active RhoA, dominant active
Rac, or control empty GFP alone vectors using Lipfectamine LTX with Plus reagent
(Invitrogen) as described by the manufacturer. The experiments were performed 24 hours
following transfection. Goat FlexiTube siRNA for StarD13, RhoA, and Rac1 were obtained
from Qiagen. The siRNAs used had the following target sequences: StarD13: Oligo 1, 5′CCCGCAATACGCTCAGTTATA-3′ and Oligo 2, 5′ATGGCTACATCCCTACTAATA-3′, RhoA: 5′-TTCGGAATGATGAGCACACAA-3′,
and Rac1: 5′-ATGCATTTCCTGGAGAATATA-3′. The cells were transfected with the
siRNA at a final concentration of 10 nM using HiPerfect (Qiagen) as described by the
manufacturer. Control cells were transfected with siRNA sequences targeting GL2
Luciferase (Qiagen). After 72 hours, protein levels in total cell lysates were analyzed by
western blotting using the appropriate antibodies or the effect of the corresponding knock
down was assayed.
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Pull down assays and Western Blots
The pull-down assays were performed using the RhoA/Rac1/Cdc42 Activation Assay
Combo Kit (Cell BioLabs) following the manufacturer’s instructions. Briefly, cell lysates
were incubated with GST-RBD (for Rho pull down) or GST-CRIB (for Rac pull down) for 1
hour at 4 °C with gentle agitation. Then, the samples were centrifuged, and the pellet
washed for several times. After the last wash, the pellets were resuspended with sample
buffer and boiled for 5 minutes. GTP-RhoA and GTP-Rac were detected by western blotting
using anti-RhoA or anti-Rac, respectively. Total RhoA/Rac and Cdc42 were collected prior
to the incubation with GST-RBD/GST-CRIB and used as a loading control. All western
blots were analyzed by ECL (GE Healthcare) followed by densitometry.
Immunostaining
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Cells were plated on cover slips, and the appropriate treatment was applied. Cells were fixed
with 4% paraformaldehyde for 10 minutes at 37°C, and permeabilized with 0.5% TritonX100 for10 minutes at room temperature. To decrease background fluorescence, cells were
rinsed with 0.1 M glycine then incubated with 0.1 M glycine for 10 minutes at room
temperature. For blocking, cells were incubated 4 times with 1% BSA, 1% FBS in PBS for 5
minutes at room temperature. Samples were stained with primary antibodies for 2 hours and
with fluorophore-conjugated secondary antibodies for 2 hours at room temperature. All
fluorescent images were taken using a 60x 1.4 NA infinity corrected optics on a Nikon
Eclipse microscope supplemented with a computer-driven Roper cooled CCD camera and
operated by IPLab Spectrum software (VayTek).
Wound healing and motility assays
Cells were grown to confluence on culture plates and a wound was made in the monolayer
with a sterile pipette tip. After wounding, the cells were washed to remove debris and new
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low-serum medium (containing 0.5% FBS) was added. Phase-contrast images of the
wounded area were taken at 0 and 24 hours after wounding using a 10X objective. Wound
widths were measured at 11 different points for each wound, and the average rate of wound
closure was calculated in μm/hr. For motility analysis, images of cells moving randomly in
serum were collected every 60 seconds for 2 hours using a 20X objective. During imaging,
the temperature was controlled using a Nikon heating stage which was set at 37 °C. The
medium was buffered using HEPES and overlayed with mineral oil. The speed of cell
movement was quantified using the ROI tracker plugin in the ImageJ software, written by
Dr. David Entenberg. This was used to calculate the total distance travelled by individual
cells. The speed is then calculated by dividing this distance by the time (120 minutes) and
reported in μm/min. The speed of at least 15 cells for each condition was calculated. The net
distance travelled by the cell was calculated by measuring the distance travelled between the
first and the last frames. Both assays were done using infinity corrected optics on a Nikon
Eclipse microscope supplemented with a computer-driven Roper cooled CCD camera and
operated by IPLab Spectrum software (VayTek).
RhoA FRET biosensor imaging and analysis
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SF268 cells were transfected with 1 μg of the RhoA FLARE biosensor, a fluorescence
resonance energy transfer (FRET)-based biosensor plasmid described earlier [13]. FRET
image sequences were obtained with an automated Olympus IX70 microscope equipped
with filter wheels in the excitation and emission light path and coupled to a cooled
SensiCam QE CCD camera (Cooke Corp., MI). CFP was excited using a S430/25 filter with
a Sutter DG4 illuminator (Sutter Instruments, Novato, CA) and the fluorescence detected
with a S470/30 (donor image) or S535/30 (FRET image) emission filter. YFP was imaged
with exciter S500/20 and emitter S535/30 (YFP image). In all cases a dual-band dichroic
mirror 86002v2bs was used (Chroma Technology Corp., VT). Images were background
corrected and the YFP images were thresholded to generate a binary mask with values of 1
within the cell and 0 for the background. The increase in FRET signal due to activation of
RhoA was detected by ratioing the FRET image (CFP excitation- YFP emission) to the
donor image (CFP excitation- CFP emission). FRET signals were quantified by averaging
the mean FRET ratio in cells. For the live FRET movies, the cells were transfected with the
RhoA biosensor as described above, and images of the cells moving randomly in serum
were taken at a 1 minute time interval for 1 hour. The images from each frame were
analyzed as described above. Detailed description of the image analysis process is described
in [24].
TIRF imaging of RhoA activity and mCherry-Paxillin
Astrocytoma cells (SF268) were transfected with 500ng of the RhoA biosensor plasmid and
500ng of the mCherry-Paxillin plasmid using Fugene6. Twenty four hours after transfection,
cells were plated onto glass coverslips and allowed to attach for a further 24 hrs prior to
imaging. During imaging cells were maintained in Ham’s F12(K) (Caisson Labs),
supplemented with 5% FBS, at 37°C using a heated stage insert (20/20 Technologies). Cells
were imaged using an Olympus IX-81 microscope equipped with a 60x 1.45NA PlanApo
TIRF objective, multi-line CELLTIRF system (Olympus) and ES Coolsnap CCD camera
(Photometrics). CFP and FRET were excited using a 440nm HeCd laser (Kimmon) and
Exp Cell Res. Author manuscript; available in PMC 2015 February 15.
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emission detected using ET470/24M and ET535/30M filters, respectively. mCherry was
excited using a 594nm Mambo diode laser (Cobolt) and emission detected using an
HQ630/40M filter. In all cases a 445/505/580 ET series dichroic mirror was used (filters and
dichroics from Chroma). Images were shade corrected and background subtracted using
Metamorph software (Molecular Devices). RhoA activity maps were derived by dividing the
FRET image by the CFP image. A detailed description of image analysis used here can be
found in [24].
Adhesion assay
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96-well plates were coated with collagen using Collagen Solution, Type I from rat tail
(Sigma) overnight at 37 °C then washed with washing buffer (0.1% BSA in DMEM). The
plates were then blocked with 0.5% BSA in DMEM at 37 °C in a CO2 incubator for 1 hour.
This was followed by washing the plates and chilling them on ice. Meanwhile, the cells were
trypsinized and counted to 4×105 cell/ml. 50 μl of cells were added in each well and
incubated at 37°C in a CO2 incubator for 30 minutes. The plates were then shaken and
washed 3 times. Cells were then fixed with 4% paraformaldehyde at room temperature for
10 minutes, washed, and stained with crystal violet (5 mg/ml in 2% ethanol) for 10 minutes.
Following the staining with crystal violet, the plates were washed extensively with water,
and left to dry completely. Crystal violet was solubilized by incubating the cells with 2%
SDS for 30 minutes. The absorption of the plates was read at 550 nm using a plate reader.
Statistical analysis
All the results reported represent average values from three independent experiments. All
error estimates are given as ± SEM. The p-values were calculated using SPSS software by
ANOVA or chi-square tests depending on the experiment.

Results
StarD13 knock down inhibits astrocytoma cell motility through modulating focal adhesion
dynamics and cell adhesion
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In order to investigate the role of StarD13 in motility of astrocytoma cells, we knocked
down its expression using siRNA oligonucleotides and confirmed the knock down by
western blot (Figure 1A and S1). We then determined the effect of StarD13 knock down on
the rate of wound closure in a wound healing assay as well as on individual cell speed and
net distance migrated in time lapse assays. The knock down of StarD13 significantly
decreased the wound closure rate (Figure 1B and C). Since Oligo 1 showed higher knock
down efficiency (Figure 1A and S1) and a more pronounced effect on cell motility in the
wound healing assay, we used this siRNA oligonucleotide to knock down the expression of
StarD13 in the following experiments. The decrease in cell migration due to StarD13 knock
down was successfully rescued by expressing a GFP-StarD13 construct (Figure 1C and S2),
which further shows that the inhibition of migration is due to the loss of StarD13 and not to
non-specific off-target effects. StarD13 knock down significantly decreased the average
speed of individual cells from 0.44 μm/min to 0.24 μm/min and the net distance migrated
from 8.5 μm to 3.02 μm (Figure 1D and E; movie S1). Altogether, these results show that the
knock down of StarD13 inhibits astrocytoma cell motility. Similar to its previously reported
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localization in HeLa cells [22], our results show that StarD13 colocalizes with two focal
adhesion markers, paxillin and vinculin, in both T98G and SF268 astrocytoma cell lines
(Figure S3). To determine whether the effect of StarD13 knock down on motility is related
to its localization to focal adhesions, we examined the focal adhesion phenotype in control
and StarD13 knock down by immunostaining for paxillin, a component of focal complexes
and focal adhesions [25]. StarD13 knock down cells showed larger and more prominent
focal adhesions at the cell edge (Figure 2A) with more than two-fold increase in area of
focal adhesions (Figure 2B). StarD13 knock down cells where StarD13 was overexpressed
showed both focal complexes and focal adhesions at the cell edge (Figure 2A, upper right
panel) indicating that a normal adhesion phenotype is restored. The formation of focal
complexes and their subsequent maturation into focal adhesions has been reported to be
regulated by Rac and Rho, respectively [25–27]. We confirmed this in astrocytoma cells
since the knock down of Rac resulted in cells with no adhesion structures at the cell edge,
while cells where RhoA was knocked down showed only small punctate focal complexes
(Figure 2A, lower panel). The fact that StarD13 knock down resulted in the formation of
large focal adhesions suggested that StarD13 might be important for focal adhesion
dynamics in astrocytoma cells. To test this, we performed time lapse analysis on control or
StarD13 knock down cells that are transfected with a GFP-tagged construct of vinculin, a
component of focal adhesions [25]. While control cells showed dynamic assembly and
disassembly of adhesion structures as they migrated, StarD13 knock down cells were static
and showed longer-lived stable adhesion structures (Figure 2C and D; movie S2). Many of
the StarD13 knock down cells were also unable to detach their tails and move forward as
observed in time lapse analysis of randomly migrating cells (Figure 2E; movie S3).
Accordingly, cells where StarD13 was knocked down showed more than a two-fold increase
in adhesion to collagen matrix (Figure 2F and G).
The effect of StarD13 knock down on cell motility is through RhoA and Rac
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StarD13 was described as a GAP for RhoA and Cdc42 but not for Rac [19]. We have
previously reported that StarD13 also plays this role in astrocytoma cells through
overexpressing StarD13 [28]. In the current study, we performed pull-down assays to
determine the level of Rho GTPase activation in StarD13 knock down cells. As expected,
the knock down of StarD13 caused a decrease in RhoA activation (Figure 3A). Interestingly,
Rac activation was lower in StarD13 knock down cells as compared to control cells (Figure
3A). Based on the antagonistic relationship between RhoA and Rac in these cells as evident
by the increase in Rac activation upon RhoA knock down (Figure 3A), we hypothesized that
StarD13 could be affecting Rac activation indirectly through its activity on RhoA. This was
confirmed since the simultaneous knock down of RhoA and StarD13 prevented the decrease
in Rac activation caused by the absence of StarD13 (Figure 3A). This suggested that the
effect of StarD13 knock down on cell motility is mediated through the direct increase in
RhoA activation, the subsequent decrease in Rac activation, or both. Therefore, we next
determined the effect of knocking down Rac as well as expressing a dominant active form of
RhoA on astrocytoma cell motility. Knock down of Rac by siRNA as verified by western
blot (Figure 3B) inhibited cell motility. In the wound healing assay, Rac1 knock down
decreased wound closure rate from 8.22 μm/hr to 1.76 μm/hr (Figure 3C and D). Likewise,
there was a significant decrease in cell speed from 0.44 μm/min to 0.17 μm/min and the net
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distance migrated from 8.50 μm in controls to 1.7 μm (Figure 3E and F; movie S4).
Expression of dominant active RhoA also inhibited cell motility similar to StarD13 knock
down. In the wound healing assay, dominant active RhoA decreased wound closure rate
from 7 μm/hr to 2.7 μm/hr (Figure 4A and B). Similarly, dominant active RhoA decreased
average cell speed from 0.34 μm/min to 0.25 μm/min (Figure 4D; movie S5). A more
substantial decrease in the net path was observed in cells transfected with dominant active
RhoA from 9.31 μm to 1.43 μm (Figure 4C and D; S5).
To confirm that StarD13 knock down is affecting motility through RhoA and Rac, we
expressed dominant active Rac or knocked down RhoA in StarD13 knock down cells
(Figure 5A) and determined the effect on cell motility. The decrease in cell motility caused
by the absence of StarD13 was completely or partially reversed by the expression of
dominant active Rac and the knock down of RhoA, respectively (Figure 5B and C). When
both RhoA and Rac were knocked down in StarD13 knock down cells, the motility of cells
was almost completely inhibited (Figure 5B and C).
RhoA knockdown or dominant active Rac in StarD13 knockdown cells reverses the
stabilization of focal adhesions
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To show that constitutive activation of RhoA due to the knock down of StarD13 is leading
to the stabilization of focal adhesions, we determined the effect of knocking down RhoA in
StarD13 knock down cells on focal adhesions. This led to the abolishment of focal
adhesions, where only immature focal complexes were observed (Figure 5D). The
expression of a dominant active Rac also led to the absence of the large focal complexes
induced by the knockdown of StarD13, where both focal complexes and focal adhesions
were observed (Figure 5D). Consistently, the knockdown of both RhoA and Rac in StarD13
knockdown cells led to the complete absence of any form of adhesion (Figure 5D).
StarD13 knock down inhibits the cycling in RhoA activation
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The fact that the constitutive increase in RhoA activity either by the knockdown of StarD13
or the expression of a dominant active RhoA is inhibiting motility implies that RhoA has to
be inactivated at some point in the cell motility cycle for the cells to move efficiently. To
investigate this possibility, we transfected control or StarD13 knock down astrocytoma cells
with a RhoA FRET biosensor in order to determine the temporal and spatial dynamics of
RhoA activation in cells undergoing random motility. At the cell tail of control cells
(identified by a white box in the upper panel of Figure 6A), RhoA showed cycles of
activation and inactivation (Figure 6A upper panel and B; movie S6). A decline in RhoA
activation was specifically evident as the cell retracted its tail to move forward (time points
16′ and 20′). As previously described, a phenotype that was evident in cells where StarD13
was knocked down is the inability of cells to retract their tail and move forward.. FRET
analysis showed that this phenomenon was correlated with a high and persistent RhoA
activation at the tail as seen in the StarD13 knock down cells transfected with the RhoA
FRET biosensor (Figure 6A lower panel and B; movie S7). We also detected RhoA
activation at the edge of cells as well as the tail (Figure S4A). Accordingly we suspected
that, other than its effect at the cell tail, StarD13 knock down inhibits cell motility by
altering the dynamics of cell adhesions at the cell edge. Indeed, other than its cycles of
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activation and inactivation at the tail of cells undergoing motility, RhoA showed cycles of
activation and inactivation at the leading edge of cells towards the direction of movement as
well (Figure S4B). At the leading edge of protrusions, RhoA activation was more persistent
in cells where StarD13 was knocked down (Figure S5). Similar to the previously described
effect of dominant active RhoA on inhibition of cell migration, and consistent with the idea
that cycling of RhoA activity is required for efficient migration, knock down of RhoA also
inhibited cell migration in the wound healing and time lapse assays (Figure S6; movie S8).
To show that RhoA is active at the basal surface of cells, where focal adhesions are
localized, we performed TIRF-based FRET analysis on cells simultaneously transfected with
RhoA FRET biosensor and mCherry-paxillin. These studies showed that RhoA activity is
distributed at the basal surface, where high activity colocalizes with adhesive structures
(Figure 6C; movie S9). These experiments also confirmed that RhoA activity is distributed
along the whole cell edge before the cell starts migrating (Figure 6C left panel).

Discussion
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StarD13 is a Rho GAP that inhibits the activity of RhoA and Cdc42. Previous studies have
shown its inhibitory effect against RhoA in hepatocellular carcinoma cells [19] and its
localization to focal adhesions in HeLa cells [22]. StarD13 was also found to inhibit cell
motility in hepatocellular carcinoma which was consistent with its role as a tumor
suppressor [29]. However, its role in astrocytoma has never been studied. We recently
published a paper showing that StarD13 plays a role of a tumor suppressor in astrocytoma
[28]. In the current study, we investigate the role of StarD13 in astrocytoma cell motility.
This was highly intriguing given the crucial role of Rho GTPases, the downstream effectors
of StarD13, and focal adhesions to which StarD13 localizes in cell motility and tumor
invasion. To our surprise, and in contrast to its role as a tumor suppressor, the knock down
of StarD13 decreased the migration of astrocytoma cells. In order to confirm the specificity
of this effect, we used a second StarD13 siRNA oligonucleotide that also resulted in a
similar inhibition in cell motility. In addition, the expression of wild type StarD13 in cells
with StarD13 knock down was able to restore cell migration to a level similar to wild type
cells. This further confirms that the loss of StarD13 in cells transfected with the StarD13
siRNA is responsible for the decrease in cell motility observed.
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Previous reports that investigated the role of StarD13 in cell motility showed that it
negatively regulates motility [29, 30]. However, there are no previous reports on the role of
StarD13 in astrocytoma or glioblastoma cells. The discrepancy between our results and the
previous reports could be due to the fact that the dependence of migration on RhoAgoverned adhesion turnover is different in distinct cell types. Indeed, in glioblastoma, the
model that we are investigating in the current study, the aberrant increase in RhoA activity
has been linked to impaired cell migration through inducing profound morphological
changes including the rearrangement of actin into stress fibers and the formation of focal
adhesions. These changes, which are mainly linked to RhoA activity, increased the
attachment of cells to matrix and rendered them immobile [31]. In fact, there are also
contradictory results regarding the role of a closely related protein, DLC1, in cell migration.
DLC1 is a well-established tumor suppressor that has been shown to inhibit proliferation,
induce apoptosis, and suppress migration [32]. However, at least two reports show that
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DLC1 positively regulates cell migration similar to our data with DLC2. In the first report,
the proper localization of DLC1 to focal adhesions in HeLa cells has been shown to be
necessary for cell migration [33]. The other study recently reported that the silencing of
DLC1 in prostate cells significantly inhibits cell migration as determined by wound-healing
and transwell assays, which is a result similar to our findings for DLC2 [34] Indeed, in our
system, the knock down of StarD13 in HUVEC cells did not result in a significant change in
cell motility in a wound healing assay (Figure S7). Interestingly, we have previously
reported that the expression of StarD13 is higher in grade IV as compared to grade I human
astrocytoma tissues [28]. In the same report, we presented data from REMBRANDT
database showing that although the mRNA expression of StarD13 is higher in grade IV
human astrocytoma samples as compared to lower grades, it was still lower than the
expression in non-tumor tissues. This suggests that, consistent with its tumor suppressor
role, an initial decrease in StarD13 levels might contribute to the initiation of astrocytic
tumors. However, as the tumor progresses, it accumulates novel mutations that increase
StarD13 to adequate levels that would, based on our current data, provide migratory and
invasive properties to astrocytoma cells.
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In this study as well as in a previous report [28] we showed that StarD13 indeed functions as
a GAP for RhoA in astrocytoma cells. We also confirmed that StarD13 localizes to focal
adhesions in these cells since it colocalizes with paxillin and vinculin. Hence, we
hypothesized that the knock down of StarD13 led to the constitutive activation of RhoA in
focal adhesions, which in turn inhibited cell motility. In order to mimic the effect of StarD13
knock down and to determine the effect of the constitutive activation of RhoA on cell
motility, we transfected astrocytoma cells with dominant active of RhoA. Indeed, this
resulted in decreased cell motility similar to the knock down of StarD13. The decrease in
cell motility due to the constitutive activation of RhoA has been reported before in other
systems [35–38]. In fact, the correlation of RhoA expression and activity with brain tumor
progression and cell motility remains a highly debatable issue in the literature (discussed in
[39]). Our results show that the knock down of RhoA using siRNA decreases the motility of
cells. A previous study has reported that RhoA is needed for the migration of glioma cells in
response to lysophosphatidic acid (LPA), an agent that is able to strongly induce
chemokinesis and chemotaxis in human glioma cells [40]. Moreover, the use of RNA
interference to deplete mDia1, another downstream effector of Rho, inhibited both adhesion
turnover and cell polarization in rat C6 glioma cells, which rendered them unable to undergo
directed migration [41]. Indeed, a positive role of RhoA or its downstream effectors in cell
motility and invasion has been described in many cell systems [42–46]. On the other hand
however, inhibition of the RhoA effector ROCK has been shown to enhance the invasive
and migratory properties of glioblastoma cells [47]. Interestingly, we detected a decrease in
Rac activation when StarD13 was knocked down, which is consistent with the antagonistic
relationship between RhoA and Rac activity we also observed in these cells. Hence, the
inhibition of astrocytoma cell motility when StarD13 is knocked down could be secondary
to Rac inhibition caused by the constitutive activation of RhoA. To investigate this
possibility, we determined the individual effect of Rac knock down on cell motility. The
absence of Rac did indeed inhibit cell motility. Importantly, the transfection of StarD13
knock down cells with active Rac was able to completely restore cell motility to normal
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levels. The ability of dominant active Rac to restore cell motility could be due to the fact
that dominant active Rac is neutralizing the effect of StarD13 knock down on Rac inhibition,
which brings back the activation state to normal levels. Collectively, the previously
discussed observations suggest that the constitutive activation of RhoA in the absence of
StarD13 could be inhibiting cell motility either directly or indirectly through inhibiting Rac
or a combination of both.
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After verifying that StarD13 localizes to focal adhesions in astrocytoma cells, and in order to
determine the mechanism through which StarD13 knock down is inhibiting motility, we
started investigating the hypothesis that the knockdown of StarD13 leads to constitutive
activation of RhoA in focal adhesions, which leads to the stabilization of focal adhesions by
preventing their disassembly and ultimately inhibiting cell migration. A high level of focal
adhesions inhibits cell migration because of the strength of attachment to the extracellular
matrix [48]. At the tail, RhoA activation in adhesion complexes must be inhibited since tail
detachment can often be the rate-limiting step of cell migration [43]. Time-lapse movies of
StarD13 knockdown cells showed that a large proportion of cells were unable to move
forward due to their inability to retract their tail. This was accompanied by persistent
activation of RhoA at the cell tail as revealed by FRET analysis. Hence, StarD13 might be
playing a role in the inhibition of RhoA in focal adhesions at the tail of cells, which seems to
be an important event for the cells to be able to detach their tails and to pull themselves and
move forward. Our results verified this hypothesis, as StarD13 silencing induced the
formation of larger and thicker focal adhesions especially at the tail of cells. This was also
supported by the fact that cells with StarD13 knock down were more adhesive to collagen
than control cells. The increase in adhesion could have prevented the retraction of the tail,
which we suspect is the major event that impeded cell motility.
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One instance where RhoA could be needed in cell motility is for the stabilization of
protrusions through inducing the maturation of focal complexes into focal adhesions, a
process that we have shown to be inhibited in the absence of RhoA as previously discussed.
Focal complexes are small punctate structures formed behind the front of the lamellipodium
[49]. These structures do not confer enough contractility needed for cell motility [49]. Focal
complexes are precursors for focal adhesions, which appear larger in size and less persistent
[49], and are needed to provide the cell with the mechanical strength needed for the cell
body to contract and move forward [7]. However, in order for RhoA to be able to drive the
conversion of focal complexes into focal adhesions, Rac must first induce the formation of
these focal complexes. This is confirmed by our results that show the absence of both focal
complexes and focal adhesions when Rac is knocked down. On the other hand, cells showed
exaggerated focal complexes with a complete absence of focal adhesions when RhoA was
knocked down. In fibroblasts, it was shown that initial cell spreading is associated with the
formation of focal complexes and with high Rac activation [49, 50]. Formation of focal
complexes stabilizes the lamellipodium of migrating cells by binding to the ECM [8]. Some
studies described a high FAK activation during initial cell spreading, which potentiates Rac1
activation and suppresses RhoA activation [51, 52]. This initial dip in RhoA activity may
allow Rac to initiate the formation of focal complexes. This also suggests sequential roles of
Rac and RhoA in adhesion, whereby initially RhoA activation is suppressed allowing Racdependent focal complex formation and allowing the cells to spread. This is followed by
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high RhoA activation which leads to the maturation of focal complexes into focal adhesions.
The activation of RhoA possibly leads to the local inhibition of Rac in order to allow the
focal complexes to mature. As previously discussed, we did observe an increase in Rac
activation when RhoA was knocked down and a decrease in Rac activation when StarD13
was knocked down. It is classically accepted that RhoA and Rac cross-talk and that they
tend to have an inverse relationship [53]. A mechanism through which Rac inhibits Rho was
proposed, whereby Rac mediates the production of oxygen radicals which causes the
phosphorylation and activation of p190 RhoGAP. This, in turn, results in the inactivation of
Rho [54]. Recently, it was shown that Rho leads to the inhibition of Rac through the ROCKdependent Rac GAP, filamin GAP (FilGAP) [55]. Whereas ROCK inhibited Rac, mDia was
found to activate Rac in the same cells, independently of ROCK, through the Cas/DOCK180
pathway [41, 56]. The fact that the knock down of RhoA in StarD13 knockdown cells
caused the total disappearance of focal adhesions supports the idea that these structures are
caused by the constitutive activation of RhoA in the absence of StarD13. It is important to
note that no focal adhesions were observed in these cells. The knockdown of RhoA was not
able to completely reverse the inhibition in motility caused by the knockdown of StarD13, as
normal focal adhesion formation is needed for efficient cell migration. This is consistent
with the fact that the knock down of both RhoA and Rac in StarD13 knock down cells
completely paralyzed the cells.
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Our hypothesis that the knock down of StarD13 is inhibiting cell motility through the
constitutive activation of RhoA is also highly reinforced by our results showing that RhoA
undergoes cycles of activation and inactivation, and that this cycling is abolished when
StarD13 is absent. Spatio-temporal analysis of RhoA activation by time-lapse FRET showed
that the cycling of RhoA occurs at both the tail and the leading edge of cells. The inhibition
of RhoA at the leading edge of cells is most probably important for the activation of Rac and
the subsequent formation of focal contacts. FRET analysis also showed that in the absence
of StarD13 there is a persistent high activity of RhoA at the cell tail and the leading edge of
cells. Altogether, this data suggests that StarD13 is necessary for the inhibition of RhoA
both at the cell tail and at the cell front. These events are required for the tail to retract and
Rac to become active and induce the formation of focal complexes, respectively. Then, the
activation of RhoA at the cell edge is needed for these focal complexes to mature generating
the necessary tension for the cell to move forward. Importantly, through imaging of cells
using TIRF-based FRET, we were able to show that RhoA activity colocalizes with focal
adhesions at the basal surface of cells.
This paper also shows that RhoA should be activated at the leading edge of astrocytoma
cells, as previously established for breast cancer cells [14]. The role of RhoA at the edge is
to allow the maturation of Rac-mediated focal complexes into focal adhesions since the
absence of RhoA leads to the absence of focal adhesions and the accumulation of focal
complexes (this study and [14]. Even though protrusion is unaffected, the absence of focal
adhesions leads to an ineffective protrusion with not enough traction force on the ECM for
the cells to move forward [7]. In this system and in other systems in previous work [14, 57],
we have shown that defective adhesions due to inhibition of Rac or RhoA, though they do
not affect protrusion, inhibits cell motility. Hence, as we describe a need to inhibit RhoA at
the tail of cells, we also confirm the newly described role of RhoA at the leading edge of
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cancer cells undergoing movement, contrary to the canonical distribution of RhoA
activation.
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This work establishes that, in addition to the activation of RhoA needed for the stabilization
of protrusions (at the cell edge) and the generation of contractile force (along the cell body),
an equally important event in the cell motility cycle is the inactivation of RhoA in focal
adhesions at the cell tail. This is needed for the dissolution of these adhesions and the
successful retraction of the tail. This work also defines StarD13, which is probably one
member of a whole orchestra of GEFs and GAPs coordinating the activation and
inactivation of RhoA respectively, as an important regulator of the cell motility cycle. One
GAP that could also be playing such a role is DLC1, which belongs to the same family as
StarD13. It would also be intriguing to investigate a possible role for DLC1 in focal
adhesion dynamics and spatial regulation of RhoA activation.
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•

This study, for the first time, describes a tumor suppressor needed for cancer
cell motility

•

The study reconciles many reports showing contradictory roles of RhoA in cell
motility

•

The study highlights the importance of the regulation of RhoA activity in
astrocytoma cell motility

•

The study establishes StarD13 as a GAP playing a major role in this process.
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Figure 1. StarD13 is needed for cell motility
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Cells (T98G) were transfected with luciferase control siRNA or with StarD13 siRNA (2
oligos) for 72 hours. A) The cells were lysed and immunoblotted by western blot analysis
for StarD13 (upper gel) or for actin (lower gel) for loading control. B) Cells transfected with
luciferase siRNA, StarD13 siRNA, or StarD13 siRNA and GFP-StarD13 were grown in a
monolayer then wounded and left to recover the wound then imaged at the same frame after
24 hours (lower micrographs). Scale bar is 50 μm. C) Quantitation for B). Wound widths
were measured at 11 different points for each wound, and the average rate of wound closure
for the cells was calculated in μm/hr. Data are the mean −/+ SEM from 3 wound closure
movies. ** indicates that the value is significant with p<0.01. D) The net paths of projected
120 frames from 2 hour long time lapse movies of cells (SF268) transfected with luciferase
control siRNA or with StarD13 siRNA undergoing random motility in serum (different
colors represent different cells) E) Quantitation of the cell speed from D) expressed in
μm/min or the net paths shown expressed in μm. Data are the mean −/+ SEM from 15 cells.
*** indicates that the values are significant with p<0.001.
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Figure 2. Proper regulation by StarD13 of Rho GTPases is needed for adhesion dynamics and
tail detachment
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A) Representative micrographs of cells (T98G) transfected with luciferase control, StarD13
siRNA or StarD13 siRNA and GFP-StarD13 (upper panel) or RhoA and Rac siRNA (lower
panel) that were fixed and immunostained with paxillin. B) Quantitation of focal adhesion
size in cells transfected with luciferase control or StarD13 siRNA. Data are the mean +/−
SEM from 3 different experiments. C) Representative fluorescent micrographs taken from a
time lapse of cells were transfected with luciferase or StarD13 siRNA and then transfected
with GFP-vinculin and imaged while undergoing random motility in serum for 1 hour. D)
Quantitation of C) showing percentage of focal adhesions persisting more than 20 minutes
(Control n=32 and StarD13 siRNA n=23). E) Representative phase contrast micrographs
taken from a time lapse of cells were transfected with luciferase or StarD13 siRNA and
imaged while undergoing random motility in serum for 2 hours. F) Representative
micrographs of cells fixed and stained with crystal violet to detect adhesion (as described in
methods). Scale bar is 50 μm. G) Graph shows quantitation of F) where crystal violet was
solubilized and the absorption of the plates was read at 550 nm using an ELISA plate reader.
Data is measured in arbitrary units and normalized to the luciferase control. Data are the
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mean −/+ SEM from 3 experiments (15 cells/condition/experiment). ** indicates that the
value is significant with p=0.007.
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Figure 3. Effect of StarD13-RhoA on Rac activation which is needed for cell motility
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A) T98G cells were transfected with luciferase, StarD13, RhoA, or StarD13 and RhoA
siRNA for 72 hours. The cells were then lysed and incubated with GST-RBD (Rhotekin
binding domain), or with GST-CRIB (Cdc42 and Rac interactive binding domain) to pull
down active RhoA or Rac respectively. The samples were then blotted with RhoA or Rac
antibody. The lower gel in each panel is a western blot for the total cell lysates for loading
control. B) Cells (T98G) were transfected with luciferase control siRNA or with Rac siRNA
for 72 hours. The cells were lysed and immunoblotted by western blot analysis for Rac
(upper gel) or for actin (lower gel) for loading control. C) The luciferase siRNA-transfected
and Rac siRNA-transfected cells were grown in a monolayer then wounded and left to
recover the wound then imaged at the same frame after 24 hours (lower micrographs). Scale
bar is 50 μm. D) Quantitation for C). Wound widths were measured at 11 different points for
each wound, and the average rate of wound closure for the cells was calculated in μm/hr.
Data are the mean −/+ SEM from 3 wound closure movies. ** indicates that the value is
significant with p=0.001. E) The net paths of projected 120 frames from 2 hour long time
lapse movies of cells (SF268) transfected with luciferase control siRNA or with Rac siRNA
undergoing random motility in serum (different colors represent different cells) F)
Quantitation of the cell speed from F) expressed in μm/min or the net paths shown expressed
in μm. Data are the mean −/+ SEM from 15 cells. *** indicates that the values are
significant with p<0.001.
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Figure 4. Constitutively active RhoA inhibits cell motility

A) Cells (T98G) were transfected with GFP vector or dominant active RhoA construct
(RhoA DA). Cells were grown in a monolayer then wounded and left to recover the wound
then imaged at the same frame after 24 hours (lower micrographs). B) Quantitation for A).
Wound widths were measured at 11 different points for each wound, and the average rate of
wound closure was calculated in μm/hr. Data are the mean −/+ SEM from 3 wound closure
movies. * indicates that the value is significant with p=0.01. C) Cells (SF268) were
transfected with GFP vector or with GFP-RhoA-DA. The images show net paths of
projected 120 frames from 2 hour long time lapse movies of green cells undergoing random
motility in serum (different colors represent different cells). D) Quantitation of the cell
speed from D) expressed in μm/min or the net paths shown expressed in μm. Data are the
mean −/+ SEM from 15 cells. *** indicates that the values are significant with p<0.001.
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Figure 5. StarD13 regulation of focal adhesions is needed for cell motility

A) Cells were transfected with luciferase control, StarD13 and dominant active Rac,
StarD13 and RhoA siRNA, or StarD13, Rac, and RhoA siRNA, lysed and western blots of
total lysates blotted with StarD13, RhoA, Rac or actin antibodies. B) Same cells as in A)
transfected and grown in a monolayer then wounded and left to recover the wound then
imaged at the same frame after 24 hours (lower micrographs). C) Quantitation for B).
Wound widths were measured at 11 different points for each wound, and the average rate of
wound closure for the cells was calculated in μm/hr. Data are the mean −/+ SEM from 3
wound closure movies. ** indicates that the values are significant with p<0.01. D)
Representative micrographs of cells (T98G) transfected with luciferase control, StarD13 and
Rac siRNA, StarD13 and RhoA siRNA, or StarD13, Rac, and RhoA siRNA that were fixed
and immunostained with paxillin. Scale bar is 10 μm.
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Figure 6. StarD13 knockdown inhibits cycling of RhoA activity and RhoA actication co-localizes
with focal adhesions
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A) Montage of representative SF268 cells (15 cells/condition/experiment of 3 experiments)
transfected with luciferase or StarD13 siRNA and with the RhoA FRET biosensor
undergoing motility in serum with the direction of migration indicated by an arrow (frames
are 4 min apart). The lower panels for each cell types are a closeup of the area enclosed by a
white box in the upper panels. B) The graph is a quantitation of the FRET signal in the area
indicated by the shadowed area in the lower panels representing the cell tail. C) SF268 cells
were transfected with 500ng of the RhoA biosensor plasmid and 500ng of the mCherryPaxillin plasmid. The paxillin signal and the FRET signal were collected on a TIRF station.
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Figure 7.

Model of StarD13 regulation of RhoA activation at the tail and at the leading edge of
astrocytoma cells undergoing cell motility.
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